Are There Benefits to Long-Term Bisphosphonate Treatment in Multiple Myeloma (MM)? Insights From Temporal Analyses of Zoledronic Acid (ZOL) Versus Clodronate (CLO) in the MRC Myeloma IX Trial.
From ASCO 2011 -- A discussion with Gareth J. Morgan, MD and Professor of Haematology in the Department of Haemato-Oncology, at The Royal Marsden Hospital in the UK
Link to this comment:
All Comments (0)